70.10.Z - Activities of head office and holding companies, excluding financial holding companies
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
58 - Publishing activities
68 - Real estate activities
69 - Legal and accounting activities
70.21.Z - Public relations and communication activities
70.22.Z - Business and other management consultancy activities
72 - Scientific research and development
77 - Rental and leasing activities
85 - Education
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | 0,3 | 0 | -90,9 | |
Gross profit (loss) | 0,5 | 0,3 | 0 | -92,1 |
EBITDA | 0,3 | 0 | -90,2 | |
Short time liabilities | 0 | 0 | -41,4 | |
Other operating costs | 0 | 0 | 485,9 | |
Income tax | 0 | 332,6 | ||
Equity capital | 1 | 1,3 | 1,4 | 1,7 |
Operating profit (EBIT) | 0,3 | 0 | -92,1 | |
Assets | 1,1 | 1,4 | 1,4 | 1 |
Net profit (loss) | 0,5 | 0,3 | 0 | -92,2 |
Cash | 0 | 0 | -26,1 | |
Net income from sale | 0,5 | 0,2 | -60,4 | |
Liabilities and provisions for liabilities | 0 | 0 | 0 | -41,4 |
Working assets | 0,3 | 0,2 | 0,2 | 9,9 |
Other income costs | 0 | 0 | -100 | |
Depreciation | 0 | 0 | 107,6 | |
Basic operational activity income | 0,7 | 246 | ||
% | % | % | p.p. | |
Profitability of capital | 46,8 | 22,5 | 1,7 | -20,8 |
Equity capital to total assets | 98,1 | 98,2 | 98,9 | 0,7 |
Gross profit margin | 73,8 | 62,2 | 12,3 | -49,9 |
EBITDA Margin | 62,8 | 15,5 | -47,3 | |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 17 | 25 | 8 | |
Current financial liquidity indicator | 7.950125694274902 | 14.914090156555176 | 6,9 | |
Net dept to EBITDA | -0.14266230165958405 | -1.0789473056793213 | -1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane